financetom
Business
financetom
/
Business
/
What's Going On With IM Cannabis Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With IM Cannabis Stock?
May 1, 2024 9:30 AM

IM Cannabis Corp. ( IMCC ) shares are trading higher Wednesday, and the stock is up more than 100% over the past five days. Here's a look at what's going on. 

The Details:

Cannabis stocks soared Tuesday following reports that the DEA will move to reschedule marijuana from a Schedule I to a Schedule III substance. IM Cannabis ( IMCC ) shares are holding the gains, while larger weed stocks including Canopy Growth Corporation ( CGC ) , Aurora Cannabis, Inc. ( ACB ) and Tilray Brands, Inc. ( TLRY ) are dropping Wednesday. 

IM Cannabis ( IMCC ) shares are moving on heavy trading volume with more than 36 million shares already traded in the session. According to data from Benzinga Pro, the stock's 100-day average volume is less than 780,000 shares.

Related News: What’s Going On With Rivian Automotive Stock?

Should I Sell My IMCC Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of IM Cannabis ( IMCC ) have gained 55.21% year to date. This compares to the average annual return of -76.64%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. IM Cannabis ( IMCC ) stock currently has an RSI of 87.37, indicating overbought conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

IMCC Price Action: According to Benzinga Pro, IM Cannabis ( IMCC ) shares are up 24.4% at $1.07 at the time of publication Wednesday.

Image: iQoncept from Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Former RTX CEO Gregory Hayes to step down as chairman
Former RTX CEO Gregory Hayes to step down as chairman
Feb 3, 2025
Feb 3 (Reuters) - Former RTX CEO Gregory Hayes will step down as executive chairman and member of the board, the aerospace and defense major said on Monday. Hayes will remain an employee of RTX as a special advisor to CEO Christopher Calio, who will take on the role of chairman of the board, the company said. The transition will...
Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand, CEO Calls It Best Quarter In 2 Years
Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand, CEO Calls It Best Quarter In 2 Years
Feb 3, 2025
Shares of Tyson Foods Inc ( TSN ) are trading higher after the first-quarter FY25 earnings result. The company reported first-quarter FY25 sales growth of 2.3% year-on-year to $13.62 billion, beating the analyst consensus estimate of $13.44 billion. Sales volume of Beef increased 5.6% Y/Y, Pork declined 0.4%, Chicken climbed 1.5%, and Prepared Foods dropped 3.2%. Gross profit surged 33%...
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab
Feb 3, 2025
08:36 AM EST, 02/03/2025 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) and AnaptysBio ( ANAB ) said Monday that they signed an agreement providing Vanda an exclusive global license to develop, manufacture, and commercialize imsidolimab. As part of the agreement, Vanda will make an upfront payment of $10 million and an additional $5 million for the existing drug supply...
Baxter's Kidney Care Segment Vantive Acquired by Carlyle Group
Baxter's Kidney Care Segment Vantive Acquired by Carlyle Group
Feb 3, 2025
08:33 AM EST, 02/03/2025 (MT Newswires) -- Baxter International's ( BAX ) former kidney care segment Vantive said Monday it has been acquired by funds managed by Carlyle Group ( CG ) . Vantive will now operate as an independent organ therapy company, it added. The deal was first announced by Baxter and Carlyle in August, under which Carlyle agreed...
Copyright 2023-2025 - www.financetom.com All Rights Reserved